Company Description
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.
It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD).
It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests.
It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations.
It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access.
It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories.
Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color.
The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Country | United States |
IPO Date | Mar 29, 1990 |
Industry | Medical - Diagnostics & Research |
Sector | Healthcare |
Employees | 67,000 |
CEO | Adam H. Schechter |
Contact Details
Address: 358 South Main Street Burlington, North Carolina United States | |
Website | https://www.labcorp.com |
Stock Details
Ticker Symbol | LH |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000920148 |
CUSIP Number | 50540R409 |
ISIN Number | US50540R4092 |
Employer ID | 13-3757370 |
SIC Code | 8071 |
Key Executives
Name | Position |
---|---|
Adam H. Schechter | President, Chief Executive Officer & Chairman |
Glenn A. Eisenberg | Special Advisor to the Chief Executive Officer |
Julia Wang | Chief Financial Officer & Executive Vice President |
Mark S. Schroeder | Executive Vice President, President of Diagnostics Laboratories & Chief Operating Officer |
Sandra D. van der Vaart J.D. | Executive Vice President, Chief Legal Officer & Corporate Secretary |
Anita Z. Graham | Executive Vice President & Chief Human Resources Officer |
Christin O'Donnell | Vice President of Investor Relations |
Dr. Brian J. Caveney J.D., M.D., M.P.H. | EVice President, President of Early Development Research Laboratories and Chief Medical & Scientific Officer |
Dr. Marcia T. Eisenberg Ph.D. | Enterprise Chief Scientific Officer & Senior Vice President |
Peter J. Wilkinson | Senior Vice President & Chief Accounting Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 04, 2024 | 4 | Filing |
Dec 04, 2024 | 4 | Filing |
Dec 04, 2024 | 4 | Filing |
Dec 03, 2024 | 3 | Filing |
Nov 26, 2024 | 4 | Filing |
Nov 25, 2024 | 4 | Filing |
Nov 19, 2024 | 8-K | Current Report |
Nov 13, 2024 | 4 | Filing |
Nov 05, 2024 | 4 | Filing |
Nov 05, 2024 | 4 | Filing |